BullFrog AI to Unveil New Precision AI Capability

GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

GlobeNewsWire • Feb 4, 2026

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI

GlobeNewsWire • Jan 6, 2026

BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration

Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today provided an update on its collaboration with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers.

GlobeNewsWire • Sep 8, 2025

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30.

GlobeNewsWire • Jul 28, 2025

Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development

From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence

GlobeNewsWire • Jul 22, 2025

BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at the upcoming XTalks webinar: AI in Bioinformatics: Overcoming Pitfalls in Statistical, ML and Generative AI Approaches.

GlobeNewsWire • Jun 20, 2025

BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery. Through this collaboration, Sygnature will introduce BullFrog Data Networks™—BullFrog's proprietary AI-driven data insights platform powered by the bfLEAP™ engine—to Sygnature's global client base of relevant biopharma companies.

GlobeNewsWire • Jun 12, 2025

BullFrog AI Issues Letter to Stockholders

GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh.

GlobeNewsWire • Dec 27, 2024

BullFrog AI Announces Appointment of Chief Financial Officer

GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer.

GlobeNewsWire • Dec 17, 2024

BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium

GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google's inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts.

GlobeNewsWire • Oct 22, 2024